Search for: "Hospira"
Results 121 - 140
of 487
Sort by Relevance
|
Sort by Date
14 Jul 2016, 2:37 pm
Hospira Inc., Federal Circuit case number 2014-1469, that to be “on sale” under pre-AIA 35 U.S.C. [read post]
14 Jul 2016, 8:09 am
Hospira an en banc Federal Circuit confirmed the validity of MedCo’s Angiomax product-by-process patent claims over an on-sale challenge. [read post]
13 Jul 2016, 4:21 pm
Hospira Inc., Case No. 14-1469 (Fed. [read post]
12 Jul 2016, 9:59 pm
By Kevin E. [read post]
11 Jul 2016, 12:28 pm
Hospira, Inc., 791F.3d 1368 (Fed. [read post]
11 Jul 2016, 7:34 am
Hospira, Inc., App. [read post]
10 Jul 2016, 10:00 pm
Hospira, Inc., the full Federal Circuit recently elaborated what exactly constitutes a "sale"for the purposes of the "on sale"bar under Pre-America Invents Act (AIA) 35 U.S.C. [read post]
28 Jun 2016, 9:08 pm
.; Hospira, Inc. [read post]
28 Jun 2016, 6:41 am
Hospira, Inc., No. 15-1210 (bright line limits on secondary indicia of nonobviousness) [CubistPetition] Vehicle Intelligence and Safety LLC v. [read post]
21 Jun 2016, 4:00 am
The appellate court did not discuss the disclosure issue. [9] Eli Lilly v Hospira 2016 FC 47 (Barnes) at para. 48 [10] The Promise was articulated by the court as the use of the compounds as antitumor agents., in vivo activity in relation to abnormal tissue or by evidence of in vitro activity from which an extrapolation of in vivo activity could be drawn. [read post]
17 Jun 2016, 8:35 am
Hospira (Fed. [read post]
3 Jun 2016, 6:40 am
Hospira, Inc., No. 15-1210 (bright line limits on secondary indicia of nonobviousness) [CubistPetition] Vehicle Intelligence and Safety LLC v. [read post]
31 May 2016, 7:24 am
Hospira. [read post]
18 May 2016, 8:19 am
Hospira that focuses on the role of secondary indicia of non-obviousness. [read post]
3 May 2016, 1:42 am
Hospira, Inc., No. 15-1210 (bright line limits on secondary indicia of nonobviousness) [CubistPetition] Post Grant Admin: MCM v. [read post]
26 Apr 2016, 7:31 am
” The Hill cites how the Department of Homeland Security and the Food and Drug Administration last year “advised hospitals to discontinue using” drug infusion pump made by Hospira after it was found to have one of the most serious “vulnerabilities. [read post]
18 Apr 2016, 9:58 am
Hospira, Inc., No. 15-1210 (bright line limits on secondary indicia of nonobviousness) [CubistPetition] Post Grant Admin: Versata v. [read post]
1 Apr 2016, 8:22 am
Hospira, the petitioner-patentee challenges the Federal Circuit’s increasingly bright line limits on secondary indicia of nonobviousness. [read post]
22 Mar 2016, 4:00 am
Although manufacturers are still fragmented, consolidations continue based on “better rationales” (given the standard merger rewards may not necessarily exist): including Pfizer/Hospira, Teva/Actavis and focused start-ups. [read post]
16 Mar 2016, 10:28 am
Hospira (Fed. [read post]
